Patent Grant

ReNeuron Group plc
17 April 2007


ReNeuron receives notice of European patent grant covering key neural stem cell
lines


Guildford, UK, 17 April 2007: ReNeuron Group plc (LSE: RENE.L) today announced
that it has received a notification of grant from the European Patent Office
concerning a patent application covering the composition, manufacture and use of
three key human neural stem cell lines.

The patent (No. 05255932.5) contains claims covering the production of the cell
lines and their use as a treatment for stroke, Huntington's disease, Alzheimer's
disease, traumatic brain injury and Creutzfeld-Jacob disease (CJD).  The patent
claims also encompass the use of these cell lines in non-therapeutic
applications such as cell-based screens for testing neurological drug
candidates.  Of the three cell lines concerned, one has been taken forward as
ReNeuron's ReN001 treatment for stroke and one is being developed as the
Company's ReN005 treatment for Huntington's disease. The third is a back-up cell
line derived from the hippocampus region of the brain.

Equivalent patent applications to the above European patent have been filed by
the Company in the US and other significant territories.  Overall, ReNeuron has
written or exclusively licensed over 55 issued patents and over 70 further
patent applications.  Of these, over 30 patents have issued in the key European
and US territories.

Dr John Sinden, Chief Scientific Officer of ReNeuron, said:

'This notice of grant represents a very important additional element in the
structure of ReNeuron's patent estate.  Our c-mycER stem cell expansion
technology allows us to generate individual cell lines as products which are
patentable entities in their own right.  This gives us the ability to extend the
life of our overall patent portfolio, and, importantly, provides us with
individually patented cell-based therapies or products that can therefore be
more readily licensed to commercial partners in due course.'


Enquiries:


ReNeuron
Michael Hunt, Chief Executive Officer                 Tel: [phone]
Dr John Sinden, Chief Scientific Officer

Financial Dynamics
David Yates                                           Tel: [phone]
Nicola Daley


Notes to Editors

ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.

ReNeuron has used its c-mycER technology to generate genetically stable neural
stem cell lines.  This technology platform has multi-national patent protection
and is fully regulated by means of a chemically-induced safety switch.  Cell
growth can therefore be completely arrested prior to in vivo implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder.  ReNeuron has also generated pre-clinical
efficacy data with its ReN005 stem cell therapy for Huntington's disease, a
genetic and fatal neurodegenerative disorder that affects around 1 in 10,000
people.  This programme is in pre-clinical development.  In addition to its
stroke and Huntington's disease programmes, ReNeuron is developing stem cell
therapies for Parkinson's disease, Type 1 diabetes and diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell(TM) range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.  ReNeuron's ReNcell(TM) 
CX and ReNcell(TM) VM neural cell lines are marketed worldwide under license by
Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.


Data sources: UK Stroke Association; American Stroke Association.


This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.

The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.



                      This information is provided by RNS
            The company news service from the London Stock Exchange